Despite the COVID-19-related disruption, the CEO’s bet on Dupixent and Vaccines paid off in Q4. The boss has now taken a shot to revitalise the slow-growing Consumer-healthcare and General-medicine businesses, along with additional cost-saving of €500m by FY22 – these measures should help Sanofi achieve its FY25 profitability target. The bolt-on strategy will continue to strengthen the pipeline, along with a key focus on six multi-blockbuster drugs. A breakthrough in the COVID-19 vaccine space c ....
